Idioma:

Disease Flare and Reactogenicity in Patients With Rheumatic and Musculoskeletal Diseases Following Two‐Dose SARS–CoV‐2 Messenger RNA Vaccination

Connolly, Caoilfhionn M. ; Ruddy, Jake A. ; Boyarsky, Brian J. ; Barbur, Iulia ; Werbel, William A. ; Geetha, Duvuru ; Garonzik‐Wang, Jacqueline M. ; Segev, Dorry L. ; Christopher‐Stine, Lisa ; Paik, Julie J.

Arthritis & rheumatology (Hoboken, N.J.), 2022-01, Vol.74 (1), p.28-32 [Periódico revisado por pares]

Boston, USA: Wiley Periodicals, Inc

Texto completo disponível

Citações Citado por

Enviar para

Título:
Disease Flare and Reactogenicity in Patients With Rheumatic and Musculoskeletal Diseases Following Two‐Dose SARS–CoV‐2 Messenger RNA Vaccination
Autor: Connolly, Caoilfhionn M. ; Ruddy, Jake A. ; Boyarsky, Brian J. ; Barbur, Iulia ; Werbel, William A. ; Geetha, Duvuru ; Garonzik‐Wang, Jacqueline M. ; Segev, Dorry L. ; Christopher‐Stine, Lisa ; Paik, Julie J.
Assuntos: 2019-nCoV Vaccine mRNA-1273 - administration & dosage ; 2019-nCoV Vaccine mRNA-1273 - adverse effects ; Adult ; Allergic reactions ; BNT162 Vaccine - administration & dosage ; BNT162 Vaccine - adverse effects ; COVID-19 - immunology ; COVID-19 - prevention & control ; Female ; Flares ; Health services ; Humans ; Hypersensitivity ; Immunization ; Immunomodulation ; Male ; Middle Aged ; mRNA ; Musculoskeletal diseases ; Musculoskeletal Diseases - immunology ; Pain ; Patients ; Prospective Studies ; Rheumatic Diseases - immunology ; SARS-CoV-2 - immunology ; Severe acute respiratory syndrome ; Symptom Flare Up ; Vaccination ; Vaccines ; Viral diseases
É parte de: Arthritis & rheumatology (Hoboken, N.J.), 2022-01, Vol.74 (1), p.28-32
Notas: This work was supported by the Ben‐Dov family. Drs. Boyarsky and Garonzik‐Wang's work was supported by the National Institute of Diabetes and Digestive and Kidney Diseases, NIH (grants F32‐DK‐124941 and K23‐DK‐115908, respectively). Dr. Segev's work was supported by the National Institute of Allergy and Infectious Diseases, NIH (grant K24‐AI‐144954). Dr. Paik's work was supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH (grant K23‐AR‐073927).
Dr. Connolly and Mr. Ruddy contributed equally to this work.
The analyses described here are the responsibility of the authors alone and do not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the US Government.
Co-senior authors
Descrição: Objective To evaluate disease flare and postvaccination reactions (reactogenicity) in patients with rheumatic and musculoskeletal diseases (RMDs) following 2‐dose SARS–CoV‐2 messenger RNA (mRNA) vaccination. Methods RMD patients (n = 1,377) who received 2‐dose SARS–CoV‐2 mRNA vaccination between December 16, 2020 and April 15, 2021 completed questionnaires detailing local and systemic reactions experienced within 7 days of each vaccine dose (dose 1 and dose 2), and 1 month after dose 2, detailing any flares of RMD. Associations between demographic/clinical characteristics and flares requiring treatment were evaluated using modified Poisson regression. Results Among the patients, 11% reported flares requiring treatment; there were no reports of severe flares. Flares were associated with prior SARS–CoV‐2 infection (incidence rate ratio [IRR] 2.09, P = 0.02), flares in the 6 months preceding vaccination (IRR 2.36, P < 0.001), and the use of combination immunomodulatory therapy (IRR 1.95, P < 0.001). The most frequently reported local and systemic reactions included injection site pain (87% after dose 1, 86% after dose 2) and fatigue (60% after dose 1, 80% after dose 2). Reactogenicity increased after dose 2, particularly for systemic reactions. No allergic reactions or SARS–CoV‐2 diagnoses were reported. Conclusion Flares of underlying RMD following SARS–CoV‐2 vaccination were uncommon. There were no reports of severe flares. Local and systemic reactions typically did not interfere with daily activity. These early safety data can help address vaccine hesitancy in RMD patients.
Editor: Boston, USA: Wiley Periodicals, Inc
Idioma: Inglês

Links

View this record in MEDLINE/PubMed

Voltar para lista de resultados

Realização: Logos de Redes Sociais:

Disease Flare and Reactogenicity in Patients With Rheumatic and Musculoskeletal Diseases Following Two‐Dose SARS–CoV‐2 Messenger RNA Vaccination

Connolly, Caoilfhionn M. ; Ruddy, Jake A. ; Boyarsky, Brian J. ; Barbur, Iulia ; Werbel, William A. ; Geetha, Duvuru ; Garonzik‐Wang, Jacqueline M. ; Segev, Dorry L. ; Christopher‐Stine, Lisa ; Paik, Julie J.

Boston, USA: Wiley Periodicals, Inc

Buscando em bases de dados remotas. Favor aguardar.